author-photo

Margaret Hills

The Royal Marsden NHS Foundation Trust

53

Papers

2592

Citations

Citation Trend

Filter By

Papers (53) Sort By

JournalConferenceOthers

CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037):

2020 Therapeutic Advances in Medical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.

2020 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (6)
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

2019 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

2018 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (10)
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance

2017 Nature Communications
Show All
- Source
- Cite
- Save
Citations (79)
Abstract P2-10-02: The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study (CRUK/07/015)

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer

2017 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (7)
Abstract P2-05-01: Clinico-pathological relationships with Ki67 in POETIC (CRUK/07/015) – Critical lessons for assessing Ki67 for prognosis and as a pharmacodynamic marker

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Integration of Ki67 with residual cancer burden (RCB) compared to Ki67 or RCB alone to predict long-term term outcome following neoadjuvant chemotherapy.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号